Irish ⁢Operations Shift: Arklow facility to ‍Close by 2028

Pharmaceutical and technology⁢ company Merck announced on Wednesday,October 18,2023,that it will close its active ‍pharmaceutical ingredient (API) production ⁢site in Arklow,County Wicklow,Ireland,by teh end of 2028,impacting approximately 100 jobs.‍ The decision follows a strategic review of the Arklow facility’s product portfolio. Consultations⁢ with employees regarding the proposed closure will begin immediately.

Despite the Arklow closure, Merck reaffirmed its commitment to⁢ Ireland with ongoing expansion plans ⁤in County Cork.The company’s recently opened ⁤€150 ⁣million filtration manufacturing facility in Blarney Business ‍Park, Cork, represents Merck’s largest life science investment to date in ireland, totaling €440 million across its Blarney and carrigtwohill operations.

Global Outlook: Healthcare ⁣Moderation, Life Science &‍ Electronics Growth

looking ahead to 2026, Merck anticipates gradual betterment in its⁣ life science and electronics sectors.⁢ However, the healthcare business is ⁣expected to experience “temporary moderation,” ⁣according to Chief financial Officer Helene⁢ von Roeder’s guidance provided last week. the company forecasts global organic sales growth in the low-to-mid single-digit percentage range for 2026.

Merck ⁣is currently targeting net sales of approximately €20.5 billion to €21.7 billion‍ for 2025. This target has been revised downwards twice this⁤ year, with chief ⁣Executive belen Garijo attributing the adjustments to unfulfilled ‍expectations ⁣related to the COVID-19 pandemic.

Strategic Realignment and Pandemic Impact

The decision to discontinue the API portfolio ⁢at Arklow reflects a broader strategic realignment within merck. The ⁣downward revision of the 2025 sales target underscores the challenges of forecasting in a post-pandemic surroundings, where‍ initial assumptions ⁢about⁤ sustained demand have not ⁤materialized.